House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Endocrinology

Diabetic foot problems: prevention and management

NICE · 2019 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE guideline NG19 covers preventing and managing foot problems in children, young people and adults with diabetes. It addresses inpatient care pathways and service organisation, foot examination, risk stratification and reassessment intervals, and how urgently to refer active problems. It also covers documenting and treating diabetic foot ulcers, investigating diabetic foot infection and osteomyelitis and choosing antibiotics for them, and diagnosing, offloading and monitoring acute Charcot arthropathy. Recommendations are dated from 2011 to 2023. Their strength is shown by wording such as 'offer', 'consider' and 'do not offer'.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Service organisation and inpatient care

  • Each hospital should have an inpatient diabetic foot care pathway, with a named consultant accountable for overall care. Refer the person to the multidisciplinary foot care service within 24 hours of the initial foot examination. Transfer care to a consultant in that service if the foot problem is the dominant clinical factor for inpatient care. [1]
  • Commissioners and providers should ensure that the following are in place: a podiatrist-led foot protection service for prevention and community care; a multidisciplinary service for problems the foot protection service cannot manage; and protocols and pathways linking care across settings. [1]

Risk assessment, stratification and surveillance

  • Give children under 12, and their families or carers, basic foot care advice. For young people aged 12 to 17, the paediatric or transitional care team should examine the feet at the annual assessment and give foot care information. The team should refer to an appropriate specialist if a problem is found or suspected. In adults, assess foot risk at diagnosis and at least annually afterwards. Also assess whenever foot problems arise, on any hospital admission, and with any change in inpatient status. [1]
  • Remove shoes, socks, bandages and dressings, then examine both feet for the listed risk factors. These include neuropathy, tested with a 10 g monofilament as part of a sensory examination, and limb ischaemia. Use ankle brachial pressure index in line with the peripheral arterial disease guideline. Interpret it carefully, because calcified arteries can falsely raise results. [1]
  • Low risk means no risk factors apart from callus alone. Moderate risk means deformity, neuropathy or peripheral arterial disease. [1]
  • High risk covers any of the following: previous ulceration or amputation; renal replacement therapy; neuropathy together with peripheral arterial disease; or neuropathy or peripheral arterial disease combined with callus and/or deformity. [1]
  • Active foot problems include ulceration, infection, chronic limb-threatening ischaemia and gangrene. They also include suspected acute Charcot arthropathy, or an unexplained hot, swollen foot with a change in colour, with or without pain. [1]
  • For low-risk people, continue foot assessments at the annual diabetes review and advise them that they could progress to moderate or high risk. Refer moderate- or high-risk people to the foot protection service. That service should see new high-risk referrals within 2 to 4 weeks and moderate-risk referrals within 6 to 8 weeks. [1]
  • Set reassessment intervals according to the person's risk. Reassess annually at low risk. At moderate risk, reassess frequently (for example every 3 to 6 months). At high risk, reassess for example every 1 to 2 months without immediate concern, or every 1 to 2 weeks with immediate concern. Consider more frequent reassessment for moderate- or high-risk people and for those unable to check their own feet. [1]

Urgency of referral for active problems

  • Refer limb- or life-threatening problems immediately to acute services and inform the multidisciplinary foot care service. Examples include ulceration with fever or signs of sepsis, and suspected deep soft tissue or bone infection. Refer other active problems within 1 working day to the multidisciplinary or foot protection service, for triage within 1 further working day. [1]

Diabetic foot ulcer

  • Document the size, depth and position of the ulcer. Grade severity with a standardised system such as SINBAD or the University of Texas classification; do not use the Wagner system. [1]
  • Offer non-removable casting for plantar neuropathic, non-ischaemic, uninfected forefoot and midfoot ulcers. Use an alternative offloading device until casting is available. [1]
  • Consider negative pressure wound therapy after surgical debridement, on the advice of the multidisciplinary foot care service. Consider dermal or skin substitutes only as an adjunct to standard care. They should be used only when healing has not progressed, and only on the advice of the multidisciplinary foot care service. [1]
  • Outside clinical trials, do not offer the following for ulcers: electrical stimulation, autologous platelet-rich plasma gel, regenerative wound matrices, dalteparin, growth factors or hyperbaric oxygen therapy. [1]

Diabetic foot infection and osteomyelitis

  • Start antibiotics for suspected infection as soon as possible. Take samples before, or as close as possible to, the start of treatment. If a wound is present, send soft tissue or bone from the base of the debrided wound; if that cannot be obtained, take a deep swab. [1]
  • Consider a foot X-ray to define the extent of the problem. Think about osteomyelitis with local infection or deep or chronic wounds. Normal inflammatory markers, X-rays or probe-to-bone testing do not exclude it. If osteomyelitis is suspected but the initial X-ray does not confirm it, consider MRI. [1]
  • For adults aged 18 years and over, use table 1 for mild infection and table 2 for moderate or severe infection. Seek specialist advice for under-18s. Give oral antibiotics first line if the person can take them and severity does not require IV treatment. Review IV antibiotics by 48 hours and consider switching to oral. Base course length on severity and clinical response, and review the need for continued antibiotics regularly. The table 2 notes state that course length is based on clinical assessment: a minimum of 7 days, and up to 6 weeks for osteomyelitis, using oral antibiotics for prolonged treatment. [1]
  • Mild infection involves only skin and subcutaneous tissue, with any erythema 0.5 cm to less than 2 cm around the ulcer. Other inflammatory causes, such as trauma, gout, acute Charcot, fracture, thrombosis and venous stasis, should be excluded. Moderate infection has erythema more than 2 cm around the ulcer, or involves deeper structures such as abscess, osteomyelitis, septic arthritis or fasciitis, without systemic inflammatory signs. Severe infection has systemic inflammatory signs, such as temperature above 38°C or below 36°C, or raised heart or respiratory rate. [1]
  • For mild infection in adults aged 18 years and over, table 1 lists four options. These are flucloxacillin 500 mg to 1 g four times a day (the 1 g upper dose was off label in August 2015), clarithromycin 500 mg twice a day, or erythromycin 500 mg four times a day in pregnancy. The fourth is doxycycline 200 mg on the first day, then 100 mg once a day, which can be increased to 200 mg daily. Each is given for 7 days; up to a further 7 days may be needed based on clinical assessment. [1]
  • For moderate or severe infection in adults aged 18 years and over, table 2 lists flucloxacillin, co-amoxiclav, co-trimoxazole (in penicillin allergy) or ceftriaxone, variously combined with gentamicin and/or metronidazole. Gentamicin starts at 5 to 7 mg/kg once a day IV, with later doses adjusted to the serum gentamicin concentration. [1]
  • Table 2 also lists piperacillin with tazobactam, and clindamycin with ciprofloxacin and/or gentamicin. For ciprofloxacin, the table cites MHRA advice on the risk of disabling and potentially long-lasting or irreversible side effects. Under that advice, fluoroquinolones must now only be prescribed when other commonly recommended antibiotics are inappropriate. [1]
  • When prescribing, advise about possible adverse effects. Also advise seeking medical help if symptoms worsen rapidly or significantly at any time, or do not start to improve within 1 to 2 days. Do not offer antibiotics to prevent diabetic foot infection; instead, advise seeking help if symptoms develop. [1]
  • Reassess suspected infection if any of the following occur: symptoms worsen rapidly or significantly at any time; they do not start to improve within 1 to 2 days; the person becomes systemically very unwell; or pain is severe and out of proportion to the infection. At reassessment, take account of other diagnoses such as pressure sores, gout or non-infected ulcers. Look for signs of serious conditions such as limb ischaemia, osteomyelitis, necrotising fasciitis or sepsis, and consider previous antibiotic use. When microbiology results are available, review the antibiotic and change to a narrow-spectrum agent if appropriate. [1]

Charcot arthropathy

  • Suspect acute Charcot arthropathy if there is redness, warmth, swelling or deformity, particularly with intact skin, and especially with peripheral neuropathy or renal failure. Think about it even when there is no deformity or pain. Refer within 1 working day to the multidisciplinary foot care service for triage within 1 further working day, and offer non-weight-bearing treatment in the meantime. Arrange a weight-bearing X-ray, and consider MRI if the X-ray is normal but suspicion remains. [1]
  • If the multidisciplinary foot care service suspects acute Charcot arthropathy, offer a non-removable offloading device; if that is not advisable because of clinical or personal circumstances, consider a removable one. Do not offer bisphosphonates outside clinical trials. Monitor treatment using clinical assessment, including the foot–skin temperature difference and serial X-rays. Resolution is likely when the temperature difference stays below 2 degrees and X-rays show no further progression. Deformity that may result from previous Charcot arthropathy carries a high ulceration risk and should be cared for by the foot protection service. [1]

Limitations and use

  • The reviewed text contains recommendations dated up to 2023 and cites MHRA January 2024 fluoroquinolone advice. It therefore reflects a version later than the 2019 date in the requested record. This summary describes the supplied version only.
  • The reviewed source did not include the research recommendations, rationale and impact sections, update history, evidence reviews or committee details.
  • Linked flowcharts and visual algorithms were available only as their alternative text.
  • The antibiotic tables are summarised selectively. Not fully reproduced here: some dosing ranges, and BNF-directed dosing for groups such as people with renal or hepatic impairment or who are pregnant or breastfeeding. Also omitted are the further table options vancomycin, teicoplanin and linezolid. The source lists linezolid only if vancomycin or teicoplanin cannot be used, for specialist use only, and presents other antibiotics as appropriate based on microbiological results and specialist advice.
  • The antibiotic tables apply to adults aged 18 years and over. Antibiotic choice for under-18s requires specialist advice, and no paediatric regimens are given.
  • Several recommendations defer to other NICE guidelines (peripheral arterial disease, pressure ulcers, cardiovascular risk, diabetes education), whose content is not included.
  • Some recommendations are not covered here, including those on accessibility, patient information, inpatient heel offloading, standard ulcer care components, debridement, dressing choice and follow-up frequency.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Diabetic foot problems: prevention and management

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
26 August 2015
Publisher’s latest update
11 October 2019
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Service organisation and inpatient care
  • Risk assessment, stratification and surveillance
  • Urgency of referral for active problems
  • Diabetic foot ulcer
  • Diabetic foot infection and osteomyelitis
  • Charcot arthropathy
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House